We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+12.76%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$478M
AUM Growth
+$56.7M
Cap. Flow
+$17.4M
Cap. Flow %
3.64%
Top 10 Hldgs %
53.49%
Holding
96
New
7
Increased
25
Reduced
16
Closed
12

Top Buys

Rank Stock Value
1
TBPH icon
Theravance Biopharma
TBPH
+$13M
2
FSTX
F-star Therapeutics, Inc. Common Stock
FSTX
+$6.09M
3
OTIC
Otonomy, Inc.
OTIC
+$4.6M
4
TBIO
Translate Bio, Inc. Common Stock
TBIO
+$2.98M
5
ARNA
Arena Pharmaceuticals Inc
ARNA
+$2.8M

Top Sells

Rank Stock Value
1
PLX icon
Protalix BioTherapeutics
PLX
+$5.37M
2
ATRC icon
AtriCure
ATRC
+$2.69M
3
ALEC icon
Alector
ALEC
+$2.57M
4
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$2.36M
5
AGTC
Applied Genetic Technologies Corporation
AGTC
+$2.18M

Sector Composition

Rank Sector Weight
1 Healthcare 90.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LMNX
26
DELISTED
Luminex Corp
LMNX
$5.12M 1.07%
139,091
-15,000
-10% -$545K
AERI
27
DELISTED
Aerie Pharmaceuticals
AERI
$4.63M 0.97%
289,040
+13,200
+5% +$226K
TVRD
28
Tvardi Therapeutics
TVRD
$19.7M
$4.5M 0.94%
8,750
+1,488
+20% +$943K
ARAY icon
29
Accuray
ARAY
$32M
$4.26M 0.89%
941,800
– –
STIM icon
30
Neuronetics
STIM
$138M
$4.07M 0.85%
253,717
– –
ACET icon
31
Adicet Bio
ACET
$85.2M
$3.87M 0.81%
23,518
-549
-2% -$112K
TPTX
32
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$3.73M 0.78%
47,852
+37,343
+355% +$2.76M
VERO
33
DELISTED
Venus Concept
VERO
$3.69M 0.77%
7,182
-275
-4% -$99.1K
MREO
34
Mereo BioPharma
MREO
$54.7M
$3.57M 0.75%
1,126,613
-123,035
-10% -$413K
MRUS
35
DELISTED
Merus
MRUS
$3.33M 0.7%
157,841
– –
RCUS icon
36
Arcus Biosciences
RCUS
$3.55B
$3.29M 0.69%
119,700
+62,100
+108% +$1.77M
RDHL
37
Redhill Biopharma
RDHL
$3.95M
$3.14M 0.66%
456
– –
PRDS
38
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$2.99M 0.63%
300,000
– –
HOOK
39
DELISTED
HOOKIPA Pharma
HOOK
$2.95M 0.62%
32,212
-2,134
-6% -$285K
VKTX icon
40
Viking Therapeutics
VKTX
$3.7B
$2.68M 0.56%
447,400
– –
SNDX icon
41
Syndax Pharmaceuticals
SNDX
$1.69B
$2.54M 0.53%
147,702
+90,202
+157% +$1.65M
NTUS
42
DELISTED
Natus Medical Inc
NTUS
$2.48M 0.52%
95,653
– –
IPSC icon
43
Century Therapeutics
IPSC
$364M
$2.35M 0.49%
+80,000
New +$2.03M
PHAS
44
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$2.24M 0.47%
603,042
– –
ASLN
45
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$2.24M 0.47%
16,938
– –
CBAY
46
DELISTED
Cymabay Therapeutics
CBAY
$2.23M 0.47%
510,386
+172,616
+51% +$765K
ETNB
47
DELISTED
89bio
ETNB
$2.18M 0.46%
116,452
+10,974
+10% +$245K
BWAY
48
Brainsway
BWAY
$611M
$2.04M 0.43%
400,000
– –
LITS
49
Lite Strategy Inc
LITS
$32.8M
$1.83M 0.38%
32,050
-250
-0.8% -$16.1K
COGT icon
50
Cogent Biosciences
COGT
$6.65B
$1.81M 0.38%
223,554
– –
1
2
3 4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
WAS
Winch Advisory Services Appleton, Wisconsin $438M AUM 17.59% 1-Year Est. Return

DAFNA Capital Management's Q2 2021 Portfolio in Review

As of Q2 2021, DAFNA Capital Management held 96 positions worth $478M, up 13% from $421M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

DAFNA Capital Management deployed $17.4M of net new capital in Q2 2021, opening 7 new positions and adding to 25 existing holdings. Its largest new stake was F-star Therapeutics, Inc. Common Stock: 714,285 shares worth $6.14M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 91% a quarter earlier.

On the sell side, the largest reduction was AtriCure, an estimated $2.69M trimmed.

  • DAFNA Capital Management's largest Q2 2021 buy was F-star Therapeutics, Inc. Common Stock: 714,285 shares worth $6.14M.
  • DAFNA Capital Management added most to Theravance Biopharma in Q2 2021, an estimated $13M increase.
  • DAFNA Capital Management's biggest Q2 2021 reduction was AtriCure, cutting an estimated $2.69M.
  • DAFNA Capital Management fully exited Protalix BioTherapeutics in Q2 2021, selling an estimated $5.37M.
  • DAFNA Capital Management's ten largest holdings make up 53% of its $478M portfolio in Q2 2021.
  • DAFNA Capital Management opened 7 new positions and closed 12 in Q2 2021.
  • DAFNA Capital Management's portfolio value rose 13% quarter-over-quarter to $478M.

Based on DAFNA Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.